Macrogenics Inc

NASDAQ:MGNX  
31.84
-0.02 (-0.06%)
4:00:00 PM EDT: $31.83 -0.01 (-0.03%)
Products

MacroGenics Announces FDA Approval Of Margenza For Patients With Pretreated Metastatic Her2-Positive Breast Cancer

Published: 12/16/2020 21:51 GMT
Macrogenics Inc (MGNX) - Macrogenics Announces FDA Approval of Margenza™ for Patients With Pretreated Metastatic Her2-positive Breast Cancer.
Macrogenics Inc - Product Launch Anticipated in March of 2021.
Macrogenics Inc - Macrogenics Anticipates That Margenza Will Be Available in March of 2021.